I hold the role of Senior Vice President, Global Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals Business Unit. In this role I address the unmet needs in four inter-related disease areas: metabolism, heart failure, cardiovascular disease and renal diseases, helping to drive our ambition to stop, reverse and cure these chronic, progressive and often time devastating diseases by maximising our medicines, delivering innovative solutions and advancing our pipeline.
I began my 30 year career in healthcare as a pharmacist and since then have helped to bring important medicines to people who have very few or limited options. I’ve joined the CVRM team with deep experience in marketing and sales, payer and access strategies, as well as leadership and engagement. Recognising the deep commitment we have in this important therapy area, I look forward to leading AstraZeneca into the future of CVRM care for the millions of people globally living with these conditions.
I joined our company more than two decades ago and have had increasing responsibility across the organisation and throughout multiple therapy areas. Most recently, I served as the SVP of US Respiratory & Immunology, delivering significant growth and expansion of the therapy area with several new product launches, including our first respiratory biologic, and the delivery of several innovative new approaches in digital health and patient centric support programs.
I’m passionate about the incredible work we are doing every day to address the unmet medical needs in order to build CVRM solutions for tomorrow. Our collective success is what happens when our work reflects our passion.
CURRENT ROLE
2019-2021
2017-2018
2016 - 2017
Featured publications
Lessons learned from the fate of AstraZeneca's drug pipeline
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. D Cook, D Brown, R Alexander, R E March, P Morgan, G Satterthwaite & M N Pangalos. Nature Reviews Drug Discovery 13, 419-431 (June 2014) | doi:10.1038/nrd4309Link: http://www.nature.com/nrd/journal/v13/n6/abs/nrd4309.html
Veeva ID: Z4-45262
Date of preparation: June 2022